Ocular Therapeutix Inc Dossier - Source-backed chat

Ocular Therapeutix Inc

OCULNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.95

Intrinsic Value $6.17median of 2 methodsbased on filings through 30 Jun 2026

Market Price $7.29Price as of 1 Oct 2026

OvervaluedIntrinsic value is 15% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.6B

Shares Outstanding 240.8M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ocular Therapeutix is transitioning into a premier retina-focused biopharmaceutical company, driven by its landmark Phase 3 SOL-1 superiority trial results for AXPAXLI in wet AMD. AXPAXLI demonstrated highly statistically significant superiority in maintaining vision compared to aflibercept, establishing a highly differentiated product profile with unmatched durability. Backed by a robust cash position of $666.7 million as of Q1 2026, which provides an operational runway into 2028, the company is well-positioned to advance its late-stage pipeline and execute its pre-commercialization strategy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$27.09

High · most bullish analyst$34.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$18.0020%

The FDA requests additional clinical data or a second superiority trial prior to NDA approval, delaying the commercial launch of AXPAXLI. Additionally, the SOL-R trial fails to meet its non-inferiority endpoints, or safety concerns emerge in the SOL-X extension study, forcing the company to raise dilutive capital as its cash runway shrinks.

Base CaseCentral scenario

$27.0950%

Matches the consensus mean

Ocular Therapeutix successfully aligns with the FDA and submits its NDA for AXPAXLI in wet AMD. The SOL-R trial meets its non-inferiority endpoints in early 2027, and the HELIOS-3 trial in diabetic retinopathy progresses steadily. Commercial preparation expenses are managed efficiently within the existing cash runway, leading to steady upward valuation as regulatory milestones are achieved.

Bull CaseUpside scenario

$34.0030%

AXPAXLI receives rapid FDA approval under the 505(b)(2) pathway based on SOL-1 superiority data, and the SOL-R non-inferiority trial delivers positive topline results in 1Q 2027. Rapid market adoption occurs due to AXPAXLI's unmatched 9-to-12 month durability, capturing significant market share from established anti-VEGF therapies and positioning the company as an attractive acquisition target for major pharmaceutical players.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Landmark Phase 3 SOL-1 trial met its primary and key secondary endpoints, demonstrating AXPAXLI's superiority over aflibercept in wet AMD.
Strong balance sheet with $666.7 million in cash and cash equivalents as of March 31, 2026, providing a runway into 2028.
Differentiated ELUTYX bioresorbable hydrogel platform offers sustained drug delivery, reducing treatment burden to 1-2 injections per year.

Key Investment Risks

Regulatory risks associated with FDA alignment on the NDA submission timeline and potential requirements for additional clinical data.
Intense commercial competition in the wet AMD space from established blockbuster anti-VEGF therapies.
High operational cash burn driven by multiple concurrent late-stage Phase 3 clinical trials (SOL-R, SOL-X, HELIOS-3).

Thesis Invalidation Triggers

FDA refusal to file or accept the AXPAXLI NDA based on the SOL-1 single-trial superiority data.
Failure of the SOL-R Phase 3 trial to demonstrate non-inferiority to aflibercept in 1Q 2027.
Unexpected serious adverse safety events emerging from the SOL-X open-label extension study.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.